Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bedaquiline - Janssen Infectious Diseases BVBA

Drug Profile

Bedaquiline - Janssen Infectious Diseases BVBA

Alternative Names: AIDS-222089; Bedaquiline fumarate; R 403323; R-207910; Sirturo; TMC-207

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson
  • Developer Global Alliance for TB Drug Development; Janssen Infectious Diseases BVBA; Janssen-Cilag; Johnson & Johnson; Pharmstandard
  • Class Antileprotics; Antituberculars; Dimethylamines; Naphthalenes; Quinolines; Small molecules
  • Mechanism of Action Adenosine triphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis; Mycobacterial infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Tuberculosis
  • Phase III Mycobacterium avium complex infections
  • Phase II Leprosy

Most Recent Events

  • 09 Jan 2024 Janssen Research & Development completes a phase II trial in Leprosy (Treatment-naive) in Brazil (PO, Tablet) (NCT03384641)
  • 19 Feb 2023 Efficacy and adverse events data from a phase III trial for Tuberculosis presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023 (CROI-2023)
  • 08 Feb 2023 Global Alliance for TB Drug Development completes a phase III trial in Tuberculosis (Combination therapy, In adults, In adolescents, In the elderly, Treatment-resistant) in Georgia, Moldova, Russia, South Africa (PO) (NCT03086486)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top